Investment Thesis
bioAffinity Technologies exhibits severe financial distress with collapsing revenues (-34.2% YoY), massive operating losses (-10.6M on 6.2M revenue), and negative cash flow (-9.4M FCF). The company is burning cash rapidly despite holding 6.4M in liquidity, with no clear path to profitability and deteriorating operational performance.
Strengths
- Positive current ratio of 2.60x indicates short-term liquidity to fund operations
- Zero long-term debt reduces financial leverage risk
- Cash position of 6.4M provides runway for operations
Risks
- Revenue declining sharply at -34.2% YoY indicating loss of market traction or customer base
- Negative free cash flow of -9.4M with burn rate unsustainable; cash will deplete in 6-8 quarters at current burn
- Gross margin of only 3.9% shows inability to achieve unit economics or scale efficiency
- Operating loss of -10.6M on 6.2M revenue demonstrates fundamental business model dysfunction
- No insider buying activity over 90 days suggests management lacks confidence in turnaround
- Net margin of -242% indicates company loses $2.42 for every dollar of revenue
Key Metrics to Watch
- Quarterly revenue trend and customer retention rates
- Operating cash flow trajectory and monthly burn rate
- Gross margin improvement and cost structure efficiency
- Cash runway remaining and path to cash flow breakeven
- Product pipeline and commercial traction metrics
Financial Metrics
Revenue
6.2M
Net Income
-14.9M
EPS (Diluted)
$-8.66
Free Cash Flow
-9.4M
Total Assets
11.0M
Cash
6.4M
Profitability Ratios
Gross Margin
3.9%
Operating Margin
-171.6%
Net Margin
-242.0%
ROE
-204.9%
ROA
-136.0%
FCF Margin
-152.4%
Balance Sheet & Liquidity
Current Ratio
2.60x
Quick Ratio
2.58x
Debt/Equity
0.00x
Debt/Assets
33.6%
Interest Coverage
-448.94x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-21T01:46:11.605955 |
Data as of: 2025-12-31 |
Powered by Claude AI